Resistance mechanisms are multifaceted, involving alterations in the tumor-immune microenvironment, dynamic changes in PD-L1 expression, compensatory activation of alternative immune checkpoints, and intrinsic tumor genomic instability [13, 14]. The gene discussed is CD274; the disease is neoplasm.